Comparative Safety Profile of the Fixed-Dose Combination Corticosteroid and Long-acting β2-Agonist Fluticasone Propionate/Formoterol Fumarate: A 36-Month Longitudinal Cohort Study in UK Primary Care.
David J PriceVictoria CarterJessica MartinElizabeth A GardenerDerek SkinnerSen YangMatthias HoffmanJenna C WillisAndrew J CooperPublished in: Drugs (2020)
The results suggest that FP/FORM was associated with an overall lower adverse outcome rate than the licensed comparators.